Background: Neutropenia during chemotherapy has been reported to be a predictor of better survival in patients with several types of cancers, although there are no reports in pretreated patients.
introduction Neutropenia due to cytotoxic chemotherapy is a common adverse event. In general, the recommended doses of cytotoxic agents are determined in dose-finding studies. However, sample sizes in this study phase are not large enough to examine individual differences in drug metabolism; therefore, toxicity profiles are likely to be highly variable [1] . In other words, a standard dose may be insufficient to achieve efficacy for some patients with faster drug elimination times [1] . In support of this hypothesis, toxicity such as neutropenia during chemotherapy has been reported to be associated with favorable clinical outcome in several types of cancer [2] [3] [4] [5] [6] [7] [8] [9] . Recently, we analyzed the long-term effects of neutropenia occurring during first-line chemotherapy with FOLFOX (infusional 5-fluorouracil and oxaliplatin) in patients with advanced colorectal cancer, using time-varying covariate (TVC) analysis [9] . Our results in addition to these other reports consistently show that patients experiencing neutropenia during chemotherapy had better prognoses compared with those without neutropenia [2] [3] [4] [5] [6] [7] [8] [9] . However, all these studies involved chemo-naive patients, and the clinical impact of neutropenia on pretreated patients who are undergoing second-line chemotherapy has not yet been reported.
Paclitaxel is most commonly used as second-line chemotherapy for advanced gastric cancer (AGC) in Japan [10] . Currently, there is an ongoing phase III study comparing weekly paclitaxel with irinotecan for second-line AGC chemotherapy. Although triweekly administration is the conventional schedule used for paclitaxel, weekly administration (dose dense) was reported to be more effective and feasible in several types of cancer, with neutropenia as the most common schedule-limiting toxicity [11, 12] . Therefore, we conducted this retrospective analysis of patients with AGC who were treated with second-line chemotherapy of weekly paclitaxel after they had progressed on prior chemotherapy in order to evaluate any possible association between neutropenia occurring during chemotherapy and survival.
patients and methods patients
This was a retrospective cohort study of AGC patients who received weekly paclitaxel (Taxol, Bristol-Myers Squibb, Tokyo, Japan) as second-line chemotherapy. Other principal inclusion criteria were as follows: the 
evaluation of neutropenia and supportive therapy
A complete blood cell count was carried out weekly before each chemotherapy. Patients with treatment delay due to toxicity were followed up with weekly or more frequent blood counts. The most severe grade of neutropenia was based on the lowest recorded neutrophil count for a given patient between the first day of paclitaxel administration and 1 week after the last paclitaxel dose was administered and was graded according to the National Cancer Institute Common Toxicity Criteria version 3.0. To evaluate neutropenia during chemotherapy, patients were divided into three categories: neutropenia absent (grade 0), mild (grades 1-2), and severe (grades 3-4). Indications for using granulocyte colony-stimulating factor (G-CSF) were not specified, but G-CSF was generally used in grade 4 or febrile neutropenia, and its use for prophylaxis was not allowed.
statistical methods
The primary objective of this study was to evaluate the association between neutropenia during weekly paclitaxel and overall survival, which was defined as the interval between the date of beginning weekly paclitaxel and the date of death or last follow-up. To evaluate the impact of neutropenia on overall survival, univariate and multivariate analyses using the Cox proportional hazards model were carried out. Therefore, a measure of association in this study was the hazard ratio (HR) along with the 95% confidence interval (95% CI). As neutropenia varies over time, analyses could be compromised by possible lead-time bias, which results in a false-positive association between chemotherapy-induced neutropenia and longer survival. Therefore, neutropenia was analyzed as a simple prognostic factor or as a TVC in all cohorts and landmark analysis cohorts to avoid this bias as much as possible. Landmark cohorts included patients who survived more than median time to treatment failure of weekly paclitaxel, which was defined as the interval between the date of the start of weekly paclitaxel administration and the last dose. Forward and backward stepwise methods were used for model building. Threshold P values for inclusion or exclusion in the model were defined as 0.10 and 0.20, respectively. Confounding variables considered in the univariate and multivariate analyses were age (<65 years versus 65 years or older), gender (male: 0 versus female: 1), ECOG PS (0-1 versus 2), histological subtype (diffuse: 0 versus intestinal: 1), disease status (advanced: 0 versus recurrent: 1), prior gastrectomy (no: 0 versus yes: 1), prior adjuvant chemotherapy (no: 0 versus yes: 1), presence of peritoneal metastasis (no: 0 versus yes: 1), presence of liver metastasis (no: 0 versus yes: 1), number of metastatic sites (1 versus 2 or more), regimen of prior chemotherapy (monotherapy: 0 versus combination: 1), duration of prior chemotherapy (<median: 0 versus ‡median: 1), prior neutrophil count (<median: 0 versus ‡median: 1), and highest grade of neutropenia during weekly paclitaxel (absent: 0 versus mild: 2 versus severe: 3). The distribution of subject characteristics was assessed by the chi-square test or the Fisher's exact test, as appropriate. Statistical analyses were carried out using STATA ver. 10 (StataCorp LP, College Station, TX). All tests were two-sided, and P values <0.05 were considered statistically significant. During treatment with weekly paclitaxel, mild neutropenia (grades 1-2) occurred in 101 patients (41.7%) and severe neutropenia (grades 3-4) occurred in 63 patients (26.0%). The other 78 patients (32.2%) did not experience neutropenia. Among the 164 patients experiencing neutropenia, the highest grade was seen during the second week (day 8) in 27, during the third week (day 15) in 75, during the fourth week (day 22) in 20, and thereafter in 42, indicating that 74.4% of patients with neutropenia experienced their highest grade within 4 weeks. In contrast, only six patients without neutropenia occurring within 4 weeks experienced late-onset neutropenia (all with mild neutropenia).
Patient characteristics categorized according to the highest grade of neutropenia experienced by each patient are shown in Table 1 . The pretreatment neutrophil count tended to be higher in patients with neutropenia. No other significant differences 
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were seen between the three neutropenia groups. The median time to treatment failure of weekly paclitaxel was 2.5 months, with a median number of paclitaxel administration of 8 (range 1-66). The median number of paclitaxel administrations was lower in patients with absent neutropenia (6, range 1-51) than in patients with mild (9, range 1-57) or severe neutropenia (10, range 1-66). In contrast, the relative dose intensity tended to be higher in the absent group. Third-line chemotherapy after weekly paclitaxel was used in a total of 115 patients (48%), with no significant differences seen between groups ( Table 1 ). The median overall survival time of all patients was 6.3 months (95% CI 5.5-7.8). Kaplan-Meier survival curves according to chemotherapy-induced neutropenia are shown in Figure 1 . The median overall survival times in the absent group, mild group, and severe group were 3.9 months (95% CI 2.7-5.2), 8.8 months (95% CI 5.9-10.4), and 8.1 months (95% CI 6.3-10.5), respectively. KaplanMeier survival curves of the landmark cohort groups (n = 208) Figure 2 . The median overall survival times in the absent group (n = 57), mild group (n = 93), and severe group (n = 58) were 5.4 months (95% CI 3.9-8.4), 9.4 months (95% CI 6.4-11.6), and 8.4 months (95% CI 6.3-10.5), respectively. Febrile neutropenia was seen in 10 patients (4.1%), which improved with G-CSF and antibiotics. G-CSF was also used in other 11 patients with grade 4 neutropenia. Grade 3 anemia was seen in eight patients, and one patient developed grade 3 thrombocytopenia. Regarding nonhematologic toxic effects, grade 2 sensory neuropathy was seen in 23 patients, and 4 patients developed grade 3 neuropathy. The incidence of other nonhematologic grades 3-4 toxic effects was low (fatigue in four patients and diarrhea in two patients). Table 2 shows the results of univariate and multivariate analyses of baseline and clinical characteristics as prognostic factors, including neutropenia. Neutropenia and other two factors (PS and number of metastatic sites) remained significant in multivariate analyses. The HR for mild neutropenia in comparison to absent neutropenia Figure 3 . Hazard ratios (HRs) for death and 95% confidence intervals (CIs). In subgroup analyses, both mild and severe neutropenia tended to be associated with improved prognosis in most subgroups.
survival analyses including neutropenia
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in comparison to absent neutropenia was 0.51 (95% CI 0.35-0.73; P < 0.001). The rightmost column of Table 2 also shows the results of multivariate regression analyses with neutropenia as a TVC. Neutropenia was still a highly statistically significant prognostic factor. The HR for mild neutropenia in comparison to absent neutropenia was 0.61 (95% CI 0.43-0.85; P = 0.004), and the HR for severe neutropenia in comparison to absent neutropenia was 0.61 (95% CI 0.41-0.88; P = 0.009). In subgroup analyses, both mild and severe neutropenia tended to be associated with improved prognosis in most subgroups (Figure 3) . Among the patients in landmark cohorts, mild and severe neutropenia remained significant prognostic factors according to survival analyses (Table 3) .
discussion
In this study, we found significantly improved survival in patients who experienced neutropenia during weekly paclitaxel administration as second-line chemotherapy for AGC. The original article Annals of Oncology frequency of neutropenia in this study is comparable to previous clinical study reports on weekly paclitaxel regimens for AGC [13, 14] . Our results indicate that both mild and severe episodes of neutropenia occurring during chemotherapy have a significant impact on the risk of death, after adjustment for baseline prognostic factors. To the best of our knowledge, this is the first evidence of this phenomenon in pretreated advanced cancer patients. From our results, we speculate that neutropenia, an indication of bone marrow suppression caused by a particular dose of chemotherapeutic agent, may also be a surrogate marker that indicates that the same dose is adequate in providing an antitumor effect. In other words, lack of neutropenia indicates an absent or weak biological effect of chemotherapy, which is possibly due to administering too low a dose to an individual patient. The causes of this interpatient variation are unclear, but genetic polymorphisms involved with drug metabolism or elimination may be among them. Since neutropenia does not exist before the initiation of chemotherapy, a false association between neutropenia and patient outcomes might have been observed because of a higher incidence of neutropenia with increasing cycles of chemotherapy in patients with better prognosis. Therefore, to answer our a priori hypothesis, analyses using the Cox proportional hazards model were carried out to remove confounding factors and neutropenia as TVCs, which is one of the strengths of this study. We further evaluated the impact of neutropenia in patients who survived >2.5 months and found that neutropenia consistently showed improved survival. Additionally, 74.4% of patients with neutropenia experienced their highest grade within 4 weeks, and those without neutropenia during the first 4 weeks rarely experienced severe late-onset neutropenia. These observations were similar to results in our previous report on patients with metastatic colorectal cancer who received FOLFOX as first-line chemotherapy [9] . These results indicate that the possibility of false-positive association by lead-time bias is low. In addition, the feasibility of a weekly paclitaxel regimen is also confirmed in our study since the frequencies of toxic effects other than neutropenia are low. These findings provide some insight for future evaluations of dose escalation in patients without neutropenia during the early course of treatment to prolong the survival. Neutropenia in earlier cycles can be used as a surrogate marker for adequate paclitaxel dose intensity, and future evaluation of this procedure is strongly warranted.
There are several methodological issues. This was a retrospective cohort study evaluating the association between neutropenia and overall survival. There are several reports that high neutrophil or leukocyte counts before treatment might be poor prognostic factors and that these patients might be less likely to experience neutropenia during treatment; however, our multivariate analysis, which included the pretreatment neutrophil counts, showed that neutropenia during chemotherapy was independently associated with prognosis. Since the median number of chemotherapy cycles was higher in patients with neutropenia compared with those without neutropenia. There might be the possibility that duration of chemotherapy itself might affect the treatment results. However, since most patients discontinued treatment due to disease progression, there might be the possibility that treatment was discontinued earlier by tumor progression due to insufficient dose. Therefore, it is questionable that duration of chemotherapy itself might affect the treatment results. The moderate sample size in this study may be a limitation, indicating that this analysis should be duplicated in another independent cohort.
In conclusion, neutropenia occurring during weekly paclitaxel treatment administered as second-line treatment to AGC patients is strongly associated with better prognosis. This may indicate that neutropenia is a surrogate marker for adequate antitumor doses of chemotherapeutic agents. An additional well-defined prospective trial that evaluates dose escalation in patients without neutropenia during the early course of treatment is warranted.
